Royalty Pharma (RPRX) Q4 2025 earnings review
Record 2025 Performance, but 2026 Guidance Signals Sharp Deceleration
Royalty Pharma capped a strong FY25 with Q4 Portfolio Receipts growing 18% YoY to $874M, driven by surges in Voranigo, Tremfya, and Trelegy. The year was marked by aggressive capital deployment ($2.6B) and the internalization of management. However, the narrative shifts drastically looking forward: 2026 guidance suggests a massive deceleration to ~3% growth at the midpoint, weighed down by generic competition for Promacta and a steep rise in interest expenses.
🐂 Bull Case
The portfolio transition is successful so far. Voranigo ($39M vs $5M YoY) and Tremfya (+44%) are rapidly scaling, effectively offsetting legacy declines. Excluding milestones, core Royalty Receipts accelerated to 17% growth in Q4.
The internalization strategy is paying off. Operating margins are expanding as the management fee is extinguished, with operating/professional costs expected to drop significantly in 2026.
🐻 Bear Case
After delivering 16% growth in FY25, management's 2026 guidance of $3.275-$3.425B implies barely 3% growth at the midpoint. This suggests the base business is facing stronger headwinds (Promacta/Imbruvica) than new launches can immediately cover.
Interest expenses are projected to jump from ~$276M in FY25 to $350-$360M in FY26. This $80M+ headwind will directly pressure free cash flow and bottom-line earnings.
⚖️ Verdict: ⚪
Neutral. The Q4 execution was excellent, demonstrating the power of the diversified model. However, the 2026 guidance reveals a 'transition year' with minimal top-line growth and rising interest costs. The thesis relies entirely on recent investments (Voranigo/Tremfya) outperforming to beat a conservative outlook.
Key Themes
Promacta and Imbruvica Drag
The impact of exclusivity losses is accelerating. Promacta royalty receipts collapsed 38% YoY in Q4 ($27M vs $44M) due to generic entry. Imbruvica continued its slide, down 13%. These two established heavyweights are now significant headwinds counteracting growth from newer assets.
Voranigo and Tremfya Surge
Voranigo has emerged as a primary growth engine, generating $39M in Q4 (up from just $5M a year ago). Similarly, Tremfya (J&J) grew 44% YoY to $56M. These two assets alone added ~$50M in incremental revenue, more than covering the declines in the legacy portfolio.
Interest Expense Headwind
Guidance for 2026 projects interest paid of $350-$360M, a sharp increase from the ~$276M paid in 2025. This reflects the cost of debt assumed during the internalization and potentially higher rates on floating components. This eats directly into the cash flow available for reinvestment or buybacks.
Internalization & Efficiency
The transition to a fully integrated company is complete. Payments for operating/professional costs in Q4 were $58M (6.6% of receipts), down from $72M (9.7%) in the prior year. Management guides these costs to decrease further in 2026, confirming the thesis that eliminating the external management fee creates structural margin expansion.
Cystic Fibrosis Franchise Resilience
Despite ongoing noise regarding disputes with Vertex (from prior quarters), the CF franchise remains a rock. Receipts grew 6% YoY to $251M in Q4. While growth is maturing, the absolute dollar contribution remains the bedrock of the portfolio, funding diversification efforts.
Other KPIs
Accelerating. Up 22% YoY, outpacing the 18% top-line growth. This demonstrates the operating leverage gained from the internalization of the manager and cost discipline.
Stable/High. The company deployed $2.6B in 2025, consistent with its long-term targets. Notable Q4 deployment included $734M for financial royalty assets (Amvuttra, zidesamtinib, neladalkib), signaling an aggressive push to refresh the pipeline before the 2026 slowdown.
Active capital return. The company repurchased 37 million shares in 2025. This reduced the diluted share count by ~5% YoY (564M vs 594M), providing a mechanical boost to per-share metrics even as growth slows.
Guidance
Decelerating significantly. The midpoint ($3.35B) implies only +2.9% YoY growth compared to the +16% achieved in 2025. This sudden braking indicates that 2026 is a transition year where new launches barely outpace patent cliffs (Promacta) and the lack of one-time milestones seen in '25.
Decelerating. Underlying royalty growth is expected to slow from the 13% achieved in 2025. While positive, the range highlights uncertainty regarding the speed of generic erosion for legacy assets versus the ramp of new launches.
Accelerating (Negative). A significant step up from the ~$276M paid in 2025. This increase is attributed to the semi-annual payment schedule of existing notes and the term loan assumed during internalization.
Key Questions
2026 Growth Bridge
With guidance implying ~3% growth at the midpoint vs 16% in 2025, specifically which assets are underperforming internal models? Is this purely Promacta/Imbruvica, or are launch curves for newer assets like Voranigo flattening?
Vertex Dispute Status
The CF franchise grew 6% this quarter, but prior quarters highlighted a dispute over royalties on the new triple combo. Has there been any progress on resolution, and does the 2026 guidance assume full payment or a discounted disputed rate?
Debt Management Strategy
With interest paid jumping to ~$355M in 2026, what is the plan for deleveraging or refinancing? Does this rising cost of capital change the hurdle rate for new royalty acquisitions?
Synthetic Royalty Pipeline
2025 was a record year for synthetic royalties (Revolution Medicines). How does the pipeline for 2026 look for similar large-scale structured deals, given the rising rate environment?